Erik Stoops
Ablynx (Belgium)(BE)ADx NeuroSciences
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Parkinson's Disease Mechanisms and Treatments, Statistical Methods in Clinical Trials, Computational Drug Discovery Methods
Most-Cited Works
- → Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease(2022)480 cited
- → Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease(2021)453 cited
- → Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected(2020)399 cited
- → Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age(2015)293 cited
- → Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology(2020)266 cited
- → Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays(2022)215 cited
- → Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231(2021)190 cited
- → Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease(2022)173 cited
- → Parkinson’s disease biomarkers based on α‐synuclein(2019)160 cited
- → How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology(2020)158 cited